JP2022517920A5 - - Google Patents

Info

Publication number
JP2022517920A5
JP2022517920A5 JP2021538762A JP2021538762A JP2022517920A5 JP 2022517920 A5 JP2022517920 A5 JP 2022517920A5 JP 2021538762 A JP2021538762 A JP 2021538762A JP 2021538762 A JP2021538762 A JP 2021538762A JP 2022517920 A5 JP2022517920 A5 JP 2022517920A5
Authority
JP
Japan
Prior art keywords
fusion protein
antibody
domain
protein according
target fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021538762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517920A (ja
Filing date
Publication date
Priority claimed from CN201910023522.6A external-priority patent/CN111423512B/zh
Application filed filed Critical
Publication of JP2022517920A publication Critical patent/JP2022517920A/ja
Publication of JP2022517920A5 publication Critical patent/JP2022517920A5/ja
Ceased legal-status Critical Current

Links

JP2021538762A 2019-01-10 2020-01-09 血管内皮細胞の増殖をブロックし、t細胞を活性化する多標的融合タンパク質、およびそれを含有する医薬組成物 Ceased JP2022517920A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910023522.6A CN111423512B (zh) 2019-01-10 2019-01-10 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
CN201910023522.6 2019-01-10
PCT/CN2020/071213 WO2020143720A1 (zh) 2019-01-10 2020-01-09 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物

Publications (2)

Publication Number Publication Date
JP2022517920A JP2022517920A (ja) 2022-03-11
JP2022517920A5 true JP2022517920A5 (cg-RX-API-DMAC10.html) 2024-03-12

Family

ID=71521813

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021538762A Ceased JP2022517920A (ja) 2019-01-10 2020-01-09 血管内皮細胞の増殖をブロックし、t細胞を活性化する多標的融合タンパク質、およびそれを含有する医薬組成物

Country Status (5)

Country Link
US (1) US20220106389A1 (cg-RX-API-DMAC10.html)
EP (1) EP3909986A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022517920A (cg-RX-API-DMAC10.html)
CN (1) CN111423512B (cg-RX-API-DMAC10.html)
WO (1) WO2020143720A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202191201A1 (ru) 2018-12-03 2022-01-26 Эдженсис, Инк. Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения
WO2021185337A1 (zh) * 2020-03-20 2021-09-23 荣昌生物制药(烟台)股份有限公司 一种双特异性融合蛋白及其应用
US20230235011A1 (en) * 2020-05-25 2023-07-27 Beijing Beyond Biotechnology Co., Ltd Fc-cd80 fusion protein and conjugates thereof and their uses
EP4205763A4 (en) * 2020-08-27 2025-01-01 Shanghai Junshi Biosciences Co., Ltd. Use of anti-pd-1 antibody in treatment of nasopharyngeal carcinoma
CN115947793B (zh) * 2021-08-13 2023-09-26 中国人民解放军总医院 靶向pd-l1的超高亲和力小蛋白及用途
CN119136822A (zh) * 2022-03-04 2024-12-13 帕诺洛斯生物科技有限公司 包括VEGF-Grab和PD-1或PD-L1拮抗剂的联合治疗组合物
IL318220A (en) * 2022-07-25 2025-03-01 Agensys Inc Methods for treating patients with locally advanced or metastatic urinary tract cancer with antibody drug conjugates (ADCs) that bind 191P4D12 proteins in combination with pembrolizumab
CN119654343A (zh) * 2022-08-09 2025-03-18 上海济煜医药科技有限公司 一种靶向pd-1和vegf的抗体及其应用
WO2024055996A1 (zh) * 2022-09-14 2024-03-21 寻济生物科技(北京)有限公司 一种抗vegfa抗体或其抗原结合片段及其应用
CN116102624B (zh) * 2023-03-07 2025-10-03 南京中医药大学 一种具有抑制血管生成作用的线性多肽及其环肽

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1916001E (pt) * 2002-03-04 2011-07-18 Imclone Llc Anticorpos humanos específicos para kdr e suas utilizações
EP1877438A2 (en) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
KR20110016959A (ko) * 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
WO2010136480A1 (en) * 2009-05-28 2010-12-02 Glaxo Group Limited Antigen-binding proteins
RU2567639C2 (ru) * 2009-06-17 2015-11-10 АббВай Биотерапеутикс Инк., Антитела против vegf и их применения
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2646007B1 (en) * 2010-12-02 2016-12-21 Neurotech USA, Inc. Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
UA122479C2 (uk) * 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
CN104195173B (zh) 2014-09-02 2017-03-08 北京比洋生物技术有限公司 具有双表达盒的谷氨酰胺合成酶高效表达载体
BR112018000366A2 (pt) * 2015-08-07 2018-09-11 Pieris Pharmaceuticals Gmbh polipeptídeo de fusão, muteína de lipocalina, molécula de ácido nucleico, célula hospedeira, métodos de produção de um polipeptídeo de fusão, para inibir simultaneamente os pontos de controle imunes, para aumentar a atividade celular de linfócitos antitumorais e para interferir com a ligação do lag-3 humano e uso do polipeptídeo de fusão
CA3001131A1 (en) * 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
CN109069638B (zh) * 2016-03-24 2022-03-29 璟尚生物制药公司 用于癌症治疗的三特异性抑制剂
CA3026518A1 (en) * 2016-06-17 2017-12-21 Genentech, Inc. Purification of multispecific antibodies
MX2019010887A (es) * 2017-03-16 2019-10-15 Alpine Immune Sciences Inc Proteinas inmunomoduladoras de cb80 variante y usos de estas.
CN108623691B (zh) * 2017-03-17 2020-05-15 北京比洋生物技术有限公司 IgG样长效免疫融合蛋白及其应用
MY200973A (en) * 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
CN109053895B (zh) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途

Similar Documents

Publication Publication Date Title
JP6124377B2 (ja) 新規抗dr5抗体
JP7196076B2 (ja) がんの処置のための抗tnf関連アポトーシス誘発リガンド受容体2及び抗カドヘリン17結合性二重特異的分子
JP2024125370A (ja) クローディン18.2結合部分およびその利用
AU2015210420B2 (en) Anti c-Met antibodies
DK2758073T3 (en) VEGF / DLL4 BINDING AGENTS AND APPLICATIONS THEREOF
JP2021526816A (ja) Dll3−cd3二重特異性抗体
JP2022515318A5 (cg-RX-API-DMAC10.html)
KR20120024763A (ko) 항axl 항체
JP2018502050A5 (cg-RX-API-DMAC10.html)
CA2706425A1 (en) Method for obtaining polypeptide constructs comprising two or more single domain antibodies
JP2013515508A5 (cg-RX-API-DMAC10.html)
JP2024001073A5 (cg-RX-API-DMAC10.html)
US20250051467A1 (en) Fap/cd40 binding molecule and medicinal use thereof
CA3208455A1 (en) Novel anti-gremlin1 antibodies
JP2022521305A (ja) 抗pd-l1抗体及びその使用
JP2023531672A (ja) H2L2とHCAb構造を有する結合タンパク質
JP2024517953A (ja) アルファ5ベータ1インテグリン結合剤及びその使用
JP2026505164A (ja) 抗cmet抗体及びその使用方法
CN120271715A (zh) 抗体及其药物偶联物和用途
CA3119458A1 (en) Methods and monitoring of treatment with vegf/dll4 binding agent
TW202328186A (zh) 抗her2抗體及其使用方法
JP2024508597A5 (cg-RX-API-DMAC10.html)
JPWO2016163433A1 (ja) 抗fgfr2抗体と他剤を含む組成物
WO2026067461A1 (en) Multispecific antibody protein and uses thereof
WO2025117872A1 (en) Bispecific antibody-like protein and methods of making and using thereof